FDA and Juul E-Cig Regs Should Keep Anti-Smoking Zealots at Bay

  • RealClearHealth | by: Peter J. Pitts and Robert M. Goldberg |
  • 11/16/2018 12:00 AM
This week FDA Commissioner Scott Gottlieb announced a plan to close the on-ramp to kids using e-cigarettes while preserving adult use of “potentially less harmful forms of nicotine delivery.” The plan's centerpiece curbs the sale of flavored e-cigarettes, which regulators claim entice youth (logic that apparently doesn't extend to Absolut Peach vodka or Jack Daniel's cinnamon whiskey), but which also help smokers quit because they don't remind them of traditional cigarettes.
 
The problem is that anti-smoking zealots want to go further and remove e-cigarettes from the market altogether while leaving most tobacco products untouched. That would snuff out the most impactful public health development in decades. The FDA’s action is designed to reduce e-cigarette use among high school and middle school students “because there is also evidence that a large percentage of these children will become addicted to nicotine and ultimately take up smoking." Yet plummeting and all-time low smoking rates – especially among young adults – would suggest otherwise. In contrast, the FDA recognizes that use of e-cigarettes can help adults stop smoking.
 
Days before the FDA's announcement, e-cigarette manufacturer Juul, which commands about 75 percent of the e-cigarette market share, self-imposed regulations to curb teen use of its products. Juul's "Youth Prevention Plan" will eliminate pod flavors, such as cucumber and mango, from the 90,000 or so retail outlets across the country.
 
Sign Up for Our Email Newsletter

RECENT NEWS

New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases

New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases

Authors argue that rare disease innovation requires learning more from fewer patients—not enrolling more patients...  Read more

Qualifying Single-Source Drug Policy, Medicare Price Negotiation, and the Incentives for Meaningful Post-Approval Innovation

Qualifying Single-Source Drug Policy, Medicare Price Negotiation, and the Incentives for Meaningful Post-Approval Innovation

CMS should demand evidence from manufacturers and be prepared to defend its own assumptions about innovation. Its next st...  Read more

Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs

Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs

Texas has an opportunity to lead rather than react. Better measurement would strengthen public confidence without diminis...  Read more

DRUGWONKS BLOG